157 related articles for article (PubMed ID: 36966503)
21. Current trends in chemotherapy for metastatic nonseminomatous testicular germ cell tumors.
Bokemeyer C
Oncology; 1998; 55(3):177-88. PubMed ID: 9560052
[TBL] [Abstract][Full Text] [Related]
22. Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
De Pasquale MD; D'Angelo P; Crocoli A; Boldrini R; Conte M; Bisogno G; Spreafico F; Inserra A; Biasoni D; Dall'Igna P; Siracusa F; Miele E; Terenziani M
Pediatr Blood Cancer; 2020 Mar; 67(3):e28125. PubMed ID: 31850649
[TBL] [Abstract][Full Text] [Related]
23. High dose chemotherapy as salvage treatment for unresectable late relapse germ cell tumors.
Lorch A; Rick O; Wündisch T; Hartmann JT; Bokemeyer C; Beyer J
J Urol; 2010 Jul; 184(1):168-73. PubMed ID: 20483152
[TBL] [Abstract][Full Text] [Related]
24. Targeted treatment approaches in refractory germ cell tumors.
Galvez-Carvajal L; Sanchez-Muñoz A; Ribelles N; Saez M; Baena J; Ruiz S; Ithurbisquy C; Alba E
Crit Rev Oncol Hematol; 2019 Nov; 143():130-138. PubMed ID: 31634730
[TBL] [Abstract][Full Text] [Related]
25. Treatment of patients with relapsed and/or cisplatin-refractory metastatic germ cell tumours: an update.
Koychev D; Oechsle K; Bokemeyer C; Honecker F
Int J Androl; 2011 Aug; 34(4 Pt 2):e266-73. PubMed ID: 21790652
[TBL] [Abstract][Full Text] [Related]
26. The importance of the dose of etoposide in the initial treatment of metastatic germ cell tumors and advances in management of patients that relapse.
Marwaha S; Venner PM; North SA
Can J Urol; 2007 Oct; 14(5):3692-6. PubMed ID: 17949524
[TBL] [Abstract][Full Text] [Related]
27. Promising novel therapies for relapsed and refractory testicular germ cell tumors.
Kozakova K; Mego M; Cheng L; Chovanec M
Expert Rev Anticancer Ther; 2021 Jan; 21(1):53-69. PubMed ID: 33138660
[TBL] [Abstract][Full Text] [Related]
28. Pharmacotherapy of relapsed metastatic testicular cancer.
Kollmannsberger C; Honecker F; Bokemeyer C
Expert Opin Pharmacother; 2008 Sep; 9(13):2259-72. PubMed ID: 18710351
[TBL] [Abstract][Full Text] [Related]
29. Current Status of Stem Cell Transplant in Treatment of Testicular Germ Cell Tumors.
King J; Adra N
Curr Oncol Rep; 2022 Mar; 24(3):303-310. PubMed ID: 35113353
[TBL] [Abstract][Full Text] [Related]
30. Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy.
Ronnen EA; Kondagunta GV; Bacik J; Marion S; Bajorin DF; Sheinfeld J; Bosl GJ; Motzer RJ
J Clin Oncol; 2005 Oct; 23(28):6999-7004. PubMed ID: 16192587
[TBL] [Abstract][Full Text] [Related]
31. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors.
Lorch A; Neubauer A; Hackenthal M; Dieing A; Hartmann JT; Rick O; Bokemeyer C; Beyer J
Ann Oncol; 2010 Apr; 21(4):820-825. PubMed ID: 19822531
[TBL] [Abstract][Full Text] [Related]
32. Risk factors in germ cell tumour patients with relapse or progressive disease after first-line chemotherapy: evaluation of a prognostic score for survival after high-dose chemotherapy.
Sammler C; Beyer J; Bokemeyer C; Hartmann JT; Rick O
Eur J Cancer; 2008 Jan; 44(2):237-43. PubMed ID: 18055194
[TBL] [Abstract][Full Text] [Related]
33. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.
Kondagunta GV; Bacik J; Donadio A; Bajorin D; Marion S; Sheinfeld J; Bosl GJ; Motzer RJ
J Clin Oncol; 2005 Sep; 23(27):6549-55. PubMed ID: 16170162
[TBL] [Abstract][Full Text] [Related]
34. Contemporary management of postchemotherapy testis cancer.
Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors in patients with relapsed or primary refractory germ cell tumors.
Rejlekova K; Mego M; Sycova-Mila Z; Obertova J; Rajec J; Salek T; Mardiak J
Neoplasma; 2009; 56(3):215-23. PubMed ID: 19309224
[TBL] [Abstract][Full Text] [Related]
36. Current Management of Disseminated Germ Cell Tumors.
Lavoie JM; Kollmannsberger CK
Urol Clin North Am; 2019 Aug; 46(3):377-388. PubMed ID: 31277732
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors.
Perez-Somarriba M; Moreno-Tejero ML; Rozas MI; Pelaez I; Madero L; Lassaletta A
Pediatr Blood Cancer; 2020 Feb; 67(2):e28089. PubMed ID: 31724795
[TBL] [Abstract][Full Text] [Related]
38. Salvage high-dose chemotherapy for germ cell tumors.
Feldman DR; Powles T
Urol Oncol; 2015 Aug; 33(8):355-62. PubMed ID: 25837842
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors.
Ashkar R; Feldman DR; Adra N; Zaid MA; Funt SA; Althouse SK; Perkins SM; Snow CI; Lazzara KM; Sego LM; Quinn DI; Hanna NH; Einhorn LH; Albany C
Invest New Drugs; 2021 Dec; 39(6):1656-1663. PubMed ID: 34031784
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Nieto Y; Tu SM; Bassett R; Jones RB; Gulbis AM; Tannir N; Kingham A; Ledesma C; Margolin K; Holmberg L; Champlin R; Pagliaro L
Ann Oncol; 2015 Oct; 26(10):2125-32. PubMed ID: 26199392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
